Breast cancer research and treatmentHumansCirculating Tumor DNABreast NeoplasmsFemaleBiomarkers
The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6.
Leandro Jonata Carvalho Oliveira, Max Senna Mano, Carlos Barrios, Rodrigo Dienstmann
Published: 202510.1007/s10549-025-07839-8
Abstract
PURPOSE: Circulating tumor DNA (ctDNA) enables early detection of ESR1 mutations in hormone receptor-positive, HER2-negative metastatic breast cancer. Building on the PADA-1, the SERENA-6 trial demonstrated significant progression-free survival and q…
Preview only. Read the full abstract at the source